ABN 16 165 160 841

ASX RELEASE **27 July 2020**

QUARTERLY ACTIVITIES AND CASH FLOW REPORTS

Melbourne, Australia, 27 July 2020: Amplia Therapeutics Ltd (ASX Code: ATX), ("Amplia" or the "Company"), a company developing new approaches for the treatment for cancer and fibrosis, is pleased to announce further progress across its small molecule, FAK inhibitor program and the release of its Appendix 4C Cash Flow Report (attached) for the quarter ending 30 June 2020.

Key Highlights

- completed the toxicology studies required to allow AMP945 to commence clinical testing which is expected to commence later in 2020; and

- secured an Orphan Drug Designation from the US FDA for the use of AMP945 to treat patients with idiopathic pulmonary fibrosis (IPF);

Operations update

During the quarter, Amplia received preliminary results from the final preclinical studies required to initiate a Phase 1 clinical trial of AMP945 in healthy volunteers. These studies were conducted by a globally recognized, pharmaceutical contract research organization under a Good Laboratory Practice (GLP) quality framework. The studies included the administration of repeat doses of AMP945 in two different species. This has allowed the identification of a No Observed Adverse Effect Level (NOAEL) which helps establish an appropriate starting dose for a Phase 1 study in healthy volunteers.

Also during the quarter, Amplia undertook much of the preparatory work required before its planned Phase 1 trial can commence. This work is now in its final stages and the trial is expected to commence dosing in late-Q3/early-Q4 of this calendar year. The Company has appointed Nucleus Network (Melbourne, Australia) to oversee and manage the clinical trial site and is preparing to submit an application to an independent Human Research Ethics Committee for approval to conduct the trial in human volunteers. The Company expects to receive the outcome of this application during the September quarter which, if approved, will allow it to initiate the inaugural Phase 1 clinical trial of AMP945.

During the quarter, Amplia received an additional Orphan Drug Designation (ODD) for AMP945 from the United States Food and Drug Administration (FDA), this time for its use in the treatment of the fibrotic disease, idiopathic pulmonary fibrosis (IPF). This follows on from the ODD for AMP945 for the treatment of pancreatic cancer which was received during the March quarter. Both Designations mean that Amplia will qualify for waived FDA fees, clinical trial protocol assistance and other incentives. Furthermore, if AMP945 secures US regulatory clearance for pancreatic cancer or IPF, it will qualify for seven years' market exclusivity in FDA-administered markets.

Financial update

Amplia finished the June 2020 quarter with cash of $691,000. During the quarter, the Company used $416,000 in operating activities, with $263,000 being used for research and development that was primarily focused on completing studies to support the Phase 1 clinical trial of AMP945.

Subsequently, the Company has initiated a fully underwritten, accelerated, non-renounceable Entitlement Offer to raise $4.0M. The institutional component of the Entitlement Offer raised $2.0M

and was strongly supported by the Company's largest shareholder, Platinum Investment Management Limited. In addition, Amplia welcomed Blueflag Holdings Pty Ltd onto its register with an initial holding of 8.7% in the Company. The retail component of the Entitlement Offer will close on Tuesday 28 July 2020.

Payments to Related Entities

In Section 6.1 of the Appendix 4C lodged for this quarter, the Company discloses salary and superannuation payments of $49,275 to the CEO/Managing Director in line with Dr Lambert's employment contract.

Outlook and future activities

Amplia's focus for the remainder of 2020 is commencement of the clinical development of AMP945 with a Phase 1 clinical trial. In parallel, the Company has initiated a program of non-clinical studies on AMP945 and AMP886 that will inform the Company's planned Phase 2 program that is currently scheduled to commence in late 2021.

The Company is also planning to initiate a program of non-clinical studies for both AMP945 and AMP886. These will evaluate the use of AMP945, both as a monotherapy and as part of a combination therapy, for the treatment of various cancers and fibrotic diseases. In addition, in partnership with the University of Melbourne, the Company is planning studies to evaluate the use of AMP886 as a standalone drug for the treatment of wet acute macular degeneration (wet-AMD).

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

For Further Information
Dr. John Lambert
CEO and Managing Director
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Amplia Therapeutics Limited	
ABN	**Quarter ended ("current quarter")**
16 165 160 841	30 June 2020

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers		
1.2	Payments for		
	(a) research and development	<263>	<263>
	(b) product manufacturing and operating costs		
	(c) advertising and marketing		
	(d) leased assets		
	(e) staff costs	<101>	<101>
	(f) administration and corporate costs	<63>	<63>
1.3	Dividends received (see note 3)		
1.4	Interest received	1	1
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives	34	34
1.8	Other (provide details if material)		
	Intellectual property costs & licence fees	<28>	<28>
	Miscellaneous	4	4
1.9	**Net cash from / (used in) operating activities**	**<416>**	**<416>**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	-	-
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	**Net cash from / (used in) financing activities**	**-**	**-**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	1,108	1,108
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<416>	<416>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	-
4.5	Effect of movement in exchange rates on cash held	<1>	<1>
4.6	**Cash and cash equivalents at end of period**	**691**	**691**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $A'000**	**Previous quarter $A'000**
5.1	Bank balances	37	104
5.2	Call deposits	654	1,004
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**691**	**1,108**

6.	**Payments to related parties of the entity and their associates**	**Current quarter $A'000**
6.1	Aggregate amount of payments to related parties and their associates included in item 1.2	49
6.2	Aggregate amount of payments to related parties and their associates included in item 2.3	-

Item 6.1 are total payments of $49,275 to the CEO/Managing Director as salary and superannuation.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (Item 1.9)	<416>
8.2	Cash and cash equivalents at quarter end (Item 4.6)	691
8.3	Unused finance facilities available at quarter end (Item 7.5)	-
8.4	Total available funding (Item 8.2 + Item 8.3)	691
8.5	**Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**	1.7

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: No. Over the next two quarters the entity expects research & development costs to increase. Refer attached Quarterly Activities Report.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes – the entity has recently announced a $4 million underwritten rights issue. The Institutional accelerated rights issue has been completed and raised $2 million and the Retail component of $2 million is due to close on 28 July.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes – (refer answer to question 2 above).

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2020

Authorised by: .John Lambert – Chief Executive Officer
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.